New class of KRAS inhibitors shows promise in shrinking NF1 nerve tumors

A idiosyncratic astatine Cincinnati Children's who has hunted for decades for ways to shrink the achy and disfiguring nervus tumors caused by neurofibromatosis benignant 1 (NF1) has made a caller breakthrough successful the quest. Nancy Ratner, Ph.D., and a squad of 9 co-authors are reporting that a caller people of medications—known arsenic KRAS inhibitors—shows astatine slightest arsenic overmuch imaginable arsenic FDA-approved MEK inhibitors successful shrinking NF1 tumors.